VYNE Therapeutics Inc
VYNE
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.07M
Close$
$23.93
16.2% downside
Current Fair Value
16.2% downsideOvervalued by 16.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.07 Million |
|---|---|
| Enterprise Value | $19.05 Million |
| Dividend Yield | $20.12 (74.42%) |
| Earnings per Share | $-31 |
| Beta | 2.01 |
| Outstanding Shares | 42,768 |
Return
| Return on Equity | -151935.89% |
|---|---|
| Return on Assets | -139870.69% |
| Return on Invested Capital | -164595.71% |
Valuation & Multiples
| P/E Ratio | -1.15 |
|---|---|
| PEG | -0.32 |
| Price to Sales | 1.3 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 19.94 |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$200,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 629.59%▲ 14.25% |
|---|---|
| Total Invested | $8.76M▲ 11.43% |
| Investors Holding | 43▲ 1.00% |
ESG Score
No data
About VYNE Therapeutics Inc
106 employeesVYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.